From Financial Modeling Prep: 2025-02-20 12:45:00

Baxter International (NYSE:BAX) stock soared over 8% after reporting strong Q4 results, with adjusted EPS of $0.58 beating estimates and revenue of $2.75 billion exceeding forecasts. Pharmaceuticals segment showed high single-digit growth, while Medical Products & Therapies saw stable results. Full year 2024 sales reached $10.64 billion with adjusted EPS of $1.89.

Baxter remains focused on achieving strategic milestones and enhancing value in healthcare sectors. The company’s 2025 outlook is positive, with Q1 adjusted EPS expected between $0.47 and $0.50. Full year EPS forecasted in the range of $2.45 to $2.55, with sales growth anticipated at 5-6%.



Read more at Financial Modeling Prep:: Baxter Jumps 8% on Q4 Earnings Beat, Strong 2025 O…